How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,104 results for

E/M Established Outpatient Visit

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Short message service (SMS) appointment reminders: A Rapid Review

Reminder Systems/ 20. exp "Appointments and Schedules"/ 21. exp Patient Compliance/ 22. Outpatients/ 23. Outpatient Clinics, Hospital/ut [Utilization] 24. Case Management/ 25. Office Visits/ 26. 8 or 9 or 10 or 11 or 12 or 13 or 14 27. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 28. 26 and 27 29. exp animals/ not humans.sh. 30. 28 not 29 Study Selection Titles and abstracts identified were exported to EndNote X7 (Thompson, Reuters, Carlsbad, California, USA). Papers identified were (...) Preference and Adherence. 2017;11:141. 9. Downing SG, Cashman C, McNamee H, Penney D, Russell DB, Hellard ME. Increasing chlamydia test of re- infection rates using SMS reminders and incentives. Sexually Transmitted Infection. 2013 Feb 1;89(1):16-9. 10. Koshy E, Car J, Majeed A. Effectiveness of mobile-phone short message service (SMS) reminders for ophthalmology outpatient appointments: observational study. BMC Ophthalmology. 2008 Dec;8(1):9. 11. Strandbygaard U, Thomsen SF, Backer V. A daily SMS

2019 Monash Health Evidence Reviews

82. Handbook on designing and implementing an immunisation information system

28 4.1. High-level considerations 28 Fundamental differences between different European contexts exist in terms of legal regulations, IIS management, and user incentives. 29 4.1.1. A ‘top-down’ centralized approach 29 4.1.2. A ‘bottom-up’ approach 31 4.2. System-level considerations 33 4.2.1. Recording immunisation event data 33 4.2.2. Data elements 36 4.2.3. Establishing the denominator 43 4.2.4. Ensuring data quality 44 4.2.5. Storing data 46 4.2.6. User access 47 4.2.7. Linkage to other (...) . 2018: Proposed council recommendation on strengthened cooperation against vaccine-preventable diseases [18]. 1.5. Information technology, e-health, and IIS E-health in the EU Ehealth is a priority of the European Commission, and is therefore at the forefront of policies and directives related to widespread digitalisation of services in the EU [1] [19]. The definition and goals of eHealth, as per the EU Directorate General on Health, are given in Box 4. Box 4. Definition and goals of eHealth

2019 European Centre for Disease Prevention and Control - Technical Guidance

83. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

advisory group that was established to support the development of this guidance. The advisory group included the ad hoc scientific panel as well as experts and observers as follows: Karin Taus (Austria) Cliona M Cheallaigh (Ireland), Núria Serre Delcor (Spain), Sally Hargreaves (United Kingdom), Hilary Kirkbride (United Kingdom), Alison Crawshaw (United Kingdom), Isabel De La Mata (European Commission), Ludovica Banfi (European Union Agency for Fundamental Rights), Olga Gorbacheva and Jenna Iodice (...) the development of this guidance: Holger Schunemann, Elie Akl, Pablo Alonso-Coello, Peter Tugwell, Robin Christensen, Vivian Welch and Joerg Meerpohl. ECDC would like to acknowledge the support and guidance provided by members of the ECDC ad hoc scientific panel established to support the development of this guidance: Angel Kunchev (Bulgaria), Gabrielle Jones (France), Anna Kuehne (Germany), Andreas Gilsdorf (Germany), Agoritsa Baka (Greece), Lelia Thornton (Ireland), Francesco Castelli (Italy), Silvia

2019 European Centre for Disease Prevention and Control - Public Health Guidance

84. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

users to send emails, e-cards or text messages to inform partners anonymously. Post-exposure prophylaxis (PEP): Use of antiretroviral therapy following exposure to HIV infection to try to prevent establishment of infection. Prevalence: Prevalence measures proportion of individuals in defined population with specific disease (or specific characteristic) at certain point in time. High, intermediate and low prevalence rates may be defined for HCV, HBV and HIV to guide testing strategies after taking (...) or belong to local migrant communities known to have high prevalence or incidence of HBV/HCV/HIV. Opt-out testing: Testing modality where patients are informed they will be tested as part of routine care, but may decline testing by raising an objection to the test. Outpatient department: Hospital department that diagnoses and treats patients without requiring an overnight stay. Outreach: Type of health service that mobilises health workers to provide services to a population away from location where

2019 European Centre for Disease Prevention and Control - Public Health Guidance

85. France has delisted anti-dementia agents

France has delisted anti-dementia agents MED CHECK - TIP December 2018/ Vol.4 No.12 · Page 29 -The Informed Prescriber C N o 12 M ED HECK D e ce m b e r 2 0 1 8 Dying Cochrane: Could it be resuscitated? Herpes zoster subunit vaccine Shingrix: Baloxavir (Xofluza®) for Influenza: No Value No difference from Tamiflu in efficacy, and suppresses immunity Cochrane review on HPV vaccine should be revised: Due to missing trials, adjuvant toxicity, mortality and healthy user bias Editorial Dying (...) while three resigned in protest. The remaining one is Dr. Gøtzsche. Among the five appointed officers, two remained, and one resigned in protest followed by resignation of another officer who opposed the decision. The other one abstained from voting, but later resigned so that there would be less appointed members in the board. This means that six members were in favor of the expulsion while the other six, including Dr. Gøtzsche, were against it. By excluding Dr. Gøtzsche from the Editorial C M ED

2019 Med Check - The Informed Prescriber

86. Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE) 1 Quality Department Guidelines for Clinical Care Ambulatory Venous Thromboembolism Guideline Team Team Leader Grant M Greenberg, MD, MA, MHSA Family Medicine Team Members Brian J Brophy, MD General Medicine Kirk A Frey, MD, PhD Nuclear Medicine James B Froehlich, MD, MPH Director, Anticoagulation Services R Van Harrison, PhD Medical Education Steven Kronick, MD Emergency Medicine Melissa A Miller, MD, MS Pulmonary & Critical Care Medicine Marc J Moote, MS, PA-C (...) Surgery David M Williams, MD Radiology Thomas W Wakefield, MD Vascular Surgery Initial Release June, 1998 Most Recent Major Update May, 2014 Interim/Minor Revision October, 2014 Ambulatory Care Guidelines Oversight Grant M Greenberg, MD, MA, MHSA R Van Harrison, PhD Literature search service Taubman Health Sciences Library For more information call: 734- 936-9771 © Regents of the University of Michigan These guidelines should not be construed as including all proper methods of care or excluding other

2020 University of Michigan Health System

87. Heart Failure - Systolic Dysfunction

Heart Failure - Systolic Dysfunction 1 Quality Department Guidelines for Clinical Care Ambulatory Heart Failure Guideline Team Team Leader William E Chavey, MD Family Medicine Team Members Barry E Bleske, PharmD Pharmacy R Van Harrison, PhD Medical Education Robert V Hogikyan, MD, MPH Geriatric Medicine Yeong Kwok, MD General Medicine John M Nicklas, MD Cardiology Consultant Todd M Koelling, MD Cardiology Initial Release August, 1999 Most Recent Major Update August, 2013 Interim/Minor Revision (...) Digoxin PRN e PRN e PRN e Ivabradine Selected patients f Selected patients f Non-pharmacologic Management Consider AICD/Bi-V pacemaker Selected patients g Yes Yes Yes HF Disease Management Yes Yes Referral to Advanced Heart Failure Program Yes Yes h Shading: = Recommended, = = Consider a One trial has demonstrated superiority of valsartan/sacubitril/ (ARNI) over enalapril in symptomatic patients. Given the lack of real world experience, either option is reasonable. ARNI should not be used

2020 University of Michigan Health System

88. Obesity Prevention and Management

with a body mass index (BMI) in the past 6 months or during the current visit documented in the medical record. (ACO, MU) Adult: Follow-up plan. If the most recent BMI is outside parameters, a follow-up plan is documented. Parameters: Age 65 and older BMI greater than or equal to 30 OR < 22; Age 18-64 BMI greater than or equal to 25 OR < 18.5. (ACO, MU) Pediatric: BMI documented. The percentage of patients 2- 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of BMI (...) Obesity Prevention and Management 1 Quality Department Guidelines for Clinical Care Ambulatory Obesity Guideline Team Team Leader Kelly A Orringer, MD Pediatrics Team Members R Van Harrison, PhD Medical Education Satyen S Nichani, MBBS General Medicine Margaret A Riley, MD Family Medicine Amy E Rothberg, MD Endocrinology Lori E Trudeau, MS, RD Nutrition Services Yvette White, RN, CPNP, MS, MHSA Ambulatory Care Services Initial Release July, 2013 Minor/Interim Revision July, 2016 Ambulatory

2020 University of Michigan Health System

89. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

FOR DIAGNOSIS AND MANAGEMENT 128 APPENDIX 2: DETAILS METHOD AND RESULTS SECTIONS OF MAIN TEXT 131 APPENDIX 3: EVIDENCE GAPS 229 PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3 WP4 4 LIST OF TABLES AND FIGURES Tables Table 0.1. UNIFI-I trial of ustekinumab versus placebo: summary of results for outcomes (clinical response, clinical remission, endoscopic healing) at week 8 in the ITT analysis 15 Table 0.2. UNIFI-M trial of ustekinumab versus placebo: summary of results (...) for clinical response, clinical remission and endoscopic healing outcomes at week 8 in the ITT analysis for the full population and BF and NBF groups 80 Table 4.11. UNIFI-M maintenance trial of ustekinumab versus placebo: summary of results for clinical response, clinical remission and endoscopic healing outcomes at week 44 in the ITT analysis for the full population and BF and NBF groups 82 Table 4.12. NMA results for clinical response for NBF patients at induction 85 Table 4.13. NMA results for clinical

2020 EUnetHTA

90. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Spread # 60 Cost (year of event): Foot ulcer $2,026 $3,039 $75,264 $14,565 $60,700 # 70 Cost (event history): Renal Disease $67,666 $101,499 $74,719 $37,172 $37,548 # 93 Cost of Outpatient visit: noninsulin $440 $659 $20,087 $55,958 $35,871 # HbA1c change: Oral Semaglutide -1.482 -0.988 $86,889 $53,769 $33,120 # 80 Mild/Moderate Hypoglycemia (Cycles 2+): Add-on Treatments 0.264 0.396 $51,113 $22,526 $28,587 # 63 Cost (year of event): Hypoglycemia Requiring ED visit $1,237 $1,856 $31,033 $58,048 (...) Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value ©Institute for Clinical and Economic Review, 2019 Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value Final Evidence Report December 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 Page i Final Evidence Report – Oral Semaglutide for Type 2 Diabetes Return to Table of Contents ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group David M. Rind, MD, MSc Chief Medical

2020 California Technology Assessment Forum

91. Curriculum for endoscopic submucosal dissection training in Europe

Western endoscopists who individually visited Japanese expert centers and observed ESD on real pa- tients [3]. However, going to Eastern countries to learn this techniqueis not feasibleformost Western endoscopists.More- over,hands-ontrainingon patientsfor foreignphysiciansis not easily nor legally allowed either in Japan or in other parts of the world. Therefore, there is a clear need for well-organized compre- hensive strategies to achieve good training in ESD. In this con- text, the European Society (...) to Western countries where they are only admitted for 1 – 2 days [68] or even treated as outpatients [69]. Never- theless, it appears that a treatment strategy with at least the possibility of admitting the patient to the hospital is fundamen- tal to forearm a serious adverse event [70]. Moreover, even though most ESD complications can be solved endoscopically, surgery may be needed in almost 1 % of procedures, particular- ly in centers with less experience [71]. For all these reasons, it is our opinion

2020 European Society of Gastrointestinal Endoscopy

92. Undernutrition in Chronic Kidney Disease

outpatient visit, taking account of changes in fluid balance and recent changes in the amount of food being eaten. People with progressive stage 4 CKD are likely to benefit from education from specialist renal dietitians in terms of advice about energy, salt, potassium and phosphate intake even if they do not flag as a concern on nutritional screening tests 15 . We suggest that established patients on dialysis should be screened every 2-3 months. If concerns arise due to intercurrent illness, screening (...) Summary 277 4 1. Introduction Background “ M aln u tri tio n ” describes both over and undernutrition. In the UK, the National Institute for Health and Care Excellence (NICE) define malnutrition as “a state in which a deficiency of nutrients such as energy, protein, vitamins and minerals causes measurable adverse effects on body composition, function or clinical o u tc o m e” in their Clinical Guideline (CG 32) 1 and Quality Standard (QS24) 2 . These guidelines suggest that patients at high risk

2019 Renal Association

93. Addressing unwarranted variation in healthcare

patient-related and non-patient related factors in thoracic aortic disease, predictors of variation in outpatient physician visits, and variation in readmission, mortality, costs and multiple process indicators in acute coronary syndrome patients. 24, 27, 28 Through combining a process of systematic review, process and structure questionnaires of cardiac surgery units and an analysis of hospital episode statistics and cardiac surgery audit data, Bottle et al (2017) 24 determined substantial regional (...) currently organised. 24 Johannsen et al (2018) 27 utilised data from 21 Swedish county councils to understand the degree of regional variation in outpatient physician visits that was explained by demand factors such as health, demography and socioeconomic indicators. Regional mortality, as a proxy for population health, and demography explained around 50% of regional variation in visits to outpatient specialists, but did not explain variation in visits to primary care physicians. Variation in primary

2019 Sax Institute Evidence Check

94. Guidelines For Professional Ultrasound Practice

SCREENING EXAMINATIONS USING ULTRASOUND 19 1.9 ERGONOMIC PRACTICE INCLUDING MANAGING THE HIGH BMI PATIENT 21 1.10 INTIMATE EXAMINATIONS AND CHAPERONES 23 1.11 EXAMINATION TIMES 24 1.12 THE 6 C’s, PATIENT IDENTIFICATION, COMMUNICATION AND CONSENT 25 1.13 CLINICAL GOVERNANCE 27 1.14 E-LEARNING FOR HEALTHCARE 29 1.15 IMAGING SERVICES ACCREDITATION SCHEME (ISAS) 29 1.16 ULTRASOUND EQUIPMENT AND QUALITY ASSURANCE TESTING 30 1.17 RAISING CONCERNS; SAFEGUARDING; STATUTORY REQUIREMENTS FOR REPORTING FEMALE (...) Guidelines for Professional Ultrasound Practice. Revision 3, December 2018 Minor amendments, March 2019. 5 Thanks is also given to J M Bridson and G Johnson of University of Liverpool, and Dr P Rowlands of The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool for their previous work on the document "Clinical Standards and framework for the assessment of initial and ongoing competence of ultrasound practitioners " (BMUS 2011) which forms the foundation for section 2.6

2019 British Medical Ultrasound Society

95. Pharmacological management of migraine

Abbreviations 34 Annexes 35 References 42 Pharmacological management of migraine Pharmacological management of migraine| 1 1 Introduction 1.1 THE NEED FOR A GUIDELINE Headache is common, with a lifetime prevalence of over 90% of the general population in the United Kingdom (UK). 1 It accounts for 4.4% of consultations in primary care and 30% of neurology outpatient consultations. 1-4 Headache disorders are classified as either primary or secondary. 5 Primary headache disorders are not associated (...) and Therapeutics Committees about the status of all newly-licensed medicines, all new formulations of existing medicines and new indications for established products. NHSScotland should take account of this advice and ensure that medicines accepted for use are made available to meet clinical need where appropriate. SMC advice relevant to this guideline is summarised in section 8.4. Pharmacological management of migraine| 5 2 Key recommendations The following recommendations were highlighted by the guideline

2018 SIGN

96. Promonitor for monitoring response to biologics in rheumatoid arthritis

making and included: costs for non-optimal treatment; outpatient and specialist visits, laboratory costs; cost of resources; and societal costs. Key outcomes The Markov model shows that after 3 years, 40% of people having adalimumab and 50% of people having infliximab would need drug treatment modifications. Costs incurred from non-optimal treatment were €1,471 per month and accumulated on clinical follow-up visits. The authors suggest that drug levels should be monitored regularly for all people (...) Promonitor for monitoring response to biologics in rheumatoid arthritis Promonitor for monitoring response to biologics Promonitor for monitoring response to biologics in rheumatoid arthritis in rheumatoid arthritis Medtech innovation briefing Published: 27 October 2017 nice.org.uk/guidance/mib126 pathways Summary Summary The technology technology described in this briefing is Promonitor. It is used to monitor response to biologic therapies. The inno innovativ vative aspect e aspect

2017 National Institute for Health and Clinical Excellence - Advice

97. Deprescribing benzodiazepine receptor agonists

if considering deprescribing Continue AP Good practice recommendation Stop AP Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia. Evidence-based clinical practice guideline. Can Fam Physician 2018;64:17-27 (Eng), e1-12 (Fr). deprescribing@bruyere.org or visit deprescribing.org for more information. Figure 1 Algorithme de déprescription des antipsychotiques (AP) Octobre 2016 Suivi toutes les une (...) , McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia. Evidence-based clinical practice guideline. Can Fam Physician 2018;64:17-27 (Eng), e1-12 (Fr). deprescribing@bruyere.org or visit deprescribing.org for more information. Algorithme de déprescription des antipsychotiques (AP) Octobre 2016 Suivi toutes les une à deux semaines pendant la réduction graduelle Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, Raman Wilms L, Rojas

2018 CPG Infobase

98. Management of opioid use disorders: a national clinical practice guideline

, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172-9. 2. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and emergency department visits due to opioid poison- ing in Canada. Ottawa: Canadian Institute for Health Information; 2016. 3. Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C (...) management (without transition to opioid agonist treatment) is pursued, provide supervised slow (> 1 mo) opioid agonist taper (in an outpatient or residential treatment setting) rather than a rapid (< 1 wk) taper. During opioid-assisted withdrawal management, patients should be transitioned to long-term addiction treatment† to help prevent relapse and associated health risks. Moderate Strong 8. For patients with a successful and sustained response to opioid agonist treatment who wish to discontinue

2018 CPG Infobase

99. Diagnosis and management of epilepsy in adults

indications for established products. SMC advice relevant to this guideline is summarised in section 11.4. Diagnosis and management of epilepsy in adults 1 • Introduction 4 | 2 Key recommendations The following recommendations were highlighted by the guideline development group as the key clinical recommendations that should be prioritised for implementation. The grade of recommendation relates to the strength of the supporting evidence on which the recommendation is based. It does not reflect (...) time for the patient and by an appropriate healthcare professional (consultant neurologist, physician with an interest in epilepsy, specialist registrar, or epilepsy nurse specialist). 2.7 MODELS OF CARE D A structured management system for patients with epilepsy should be established in primary care. As with other chronic diseases, an annual review is desirable. Diagnosis and management of epilepsy in adults 2 • Key recommendations6 | 3 Diagnosis 3.1 WHO SHOULD MAKE THE DIAGNOSIS OF EPILEPSY

2018 SIGN

100. Public health service provision by community pharmacies: a systematic map of evidence

: This report should be cited as: Stokes G, Rees R, Khatwa M, Stansfield C, Burchett H, Dickson, K, Brunton G, Thomas J (2019) Public health service provision by community pharmacies: a systematic map of evidence. London: EPPI-Centre, Social Science Research Unit, Institute of Education, University College London. Funding This report is independent research commissioned by the National Institute for Health Research (NIHR) Policy Research Programme (PRP) for the Department of Health and Social Care (DHSC (...) with a global agenda for improving healthy life expectancy through accessible, multi-disciplinary networks of community-based healthcare professionals (World Health Organization 2004; DH 2008). It is estimated there are 11,619 community pharmacies across England. It is estimated that 1.6 million people visit a pharmacy every day and that 1.2 million of these visits are for health-related reasons. (LGA 2013; PSNC 2013a). Community pharmacies are easily accessible to people seeking local healthcare (PHE 2014

2019 EPPI Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>